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There are no controlled clinical trials evaluating drug therapy in patients with ventricular arrhythmias and chronic chagasic
cardiomyopathy. Empirical treatment with disopyramide (400-1,OOOmg/d),phenytoin (4-6mg/d), mexiletine (600-1,200mg/d),
propafenone (900mg/d), amiodarone ( loading: 1,OOOmg/d,10-14 days; maintenance 200-600mg/d), and sotalol (320mg/d) had
efficacy and tolerance ranging from 18% to 90% with heterogeneous criteria for efficacy definition. Further studies with
homogenous criteria are required to determine which is the most appropriate drug therapy for patients with chronic chagasic
cardiomyopathy and ventricular arrhythmias.
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INTRODUCTION
The objectives of the treatment of cardiacarrhythmias are relief of symptoms and preventionof sudden cardiac death. The therapeutic
algorithms are born from controlled clinical studies, where
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efficacy and tolerance of these drugs are conveniently
tested in human beings. These information do not have
the mistakes originated from clinical reasoning.
The results of controlled clinical trials have important
influence in scientific community, sometimes
demonstrating that decisions guided only by clinical
intuition can be dangerous to the patients. A well-known
example occurred during the CAST study. It was
demonstrated that patients treated with cl ass IC
antiarrhythmic drugs, which are potent antiarrhythmic
agents for ventricular arrhythmias, had two to threefold
increase in the number of deaths when compared with
those who received placebo (28).
The majority of these studies deri ved from patients
with ischemic cardiomyopathy after myocardial infarction.
Unfortunately, there are few relevant studies in our country
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evaluating patients with Chagas' disease when the use of
an antiarrhythmic drug is to be considered.
CLASS IANTIARRHYTHMIC DRUGS
Group IA drugs: Only procainamide, quinidine and
disopyramide are commercially available in Brazil. There
are no adequate studies evaluating the use of such drugs
in Chagas' disease.
Slow-release procainamide is not available in Brazil.
Given intravenously, it is useful during an episode of
sustained ventricular tachycardia. A total dose of 20mg/
Kg is administered at an infusion rate of 50mg/min.
Quinidine, is commercially available in 200 mg
tablets for oral administration every 6 hour, in doses of
800-1,600mg/day. It reduces premature ventricular beats
in 36-70% of the patients.
Disopyramide is commercially available in 100 and
250mg. Drug discontinuation is mandatory in 9% of the
patients due to symptomatic bradyarrhythmias( 1,22).
Worsening of congestive heart failure, a condition very
common in chagasic cardiomyopathy, limits its use in
patients with ventricular dysfunction (19).
Group IB drugs: Lidocaine, mexiletine, and
phenytoin are commercially available in our country. When
intravenous administration is imperative and the ventricular
arrhythmia is not responsive to procainamide, lidocaine
can be used. The loading dose is 1-2mg/kg and the
maintenance dose ranges from 20 to 60mcg/kg/min.
Mexiletine is available in tablets of 200ing, and the daily
doses ranges from 600 to 1,200mg divided in 3 times doses.
Premature ventricular complex suppression was achieved
in 32%-69% but 19% of these patients had side effects
(14,15,27). Phenytoin is given orally, in doses of 4-6mg/
kg/day (3 times daily) and efficacy was demonstrated in
18% of 11 patients tested (27).
Group Ie Drugs: Flecainide and encainide were
described as potent suppressers of premature ventricular
beats (2). However, a subsequent multicentric trial showed
that these drugs should not be administered in patients
with poor left ventricular function (9,28). Propafenone,
another IC drug, is utilized orally (900mg/day), 3 times
daily with efficacy and tolerance in 41 %-66% (5,20).
It is important to stress that metanalysis of controlled
studies of group I drugs in patients with ischemic
cardiomyopathy delineated an increase in mortality in
patients treated with these drugs when compared with a
placebo group (29). Their use in chagasic cardiomyopathy,
is indicated only to' relief symptoms in selected cases.
CLASS IIANTIARRHYTHMIC DRUGS
In spite of being the most effective drugs in
preventing sudden cardiac death (29), the beta blocker have
only moderate efficacy in controlling ventricular
arrhythmias (39-56%). There are no clinical studies with
these drugs in Chagas' disease: alterations in automatism,
conduction and left ventricular dysfunction, will restrict
the use of these drugs only for selected cases.
CLASS IIIANTIARRHYTHMIC DRUGS
Experimental data and results of clinical studies
changed the trends of using sodium channel blocker (class
I drugs) to drugs that prolong the repolarization time (class
III drugs). At the present time, there is not a drug with
exclusive class III action in clinical use. Amiodarone, a
drug with multiple actions, and sotalol, a non selective
beta blocker, have potent class III action, and are included
in this group.
Amiodarone has been empirically used in our country
in all kinds of arrhythmias. Unfortunately there are no
controlled studies evaluating efficacy of this drug in
chagasic cardiomyopathy. In non-controlled studies, the
number of premature ventricular beats decreased in 35-
92% of the patients evaluated with few side effects
(3,4,13,21). The doses utilized in the majority of studies
varied from 600 to 1,200 mg for 14 days (loading phase),
followed by a medium doses of 400mg (maintenance
phase).
Patients with chronic chagasic cardiomyopathy and
sustained ventricular tachycardia are at major risk for
sudden death. In our experience, criteria of efficacy
according to Holter monitoring was found in 52% of
patients. When electrophysiologic study was used to assess
efficacy, ventricular tachycardia was not reinducible in
18% of the patients (11). None of these methods was able
to predict clinical efficacy of this drug. The worst prognosis
during amiodarone therapy was observed in patients with
congestive heart failure (6,24).
Sotalol, another class III antiarrhythmic drug, also
has a beta-blocker action, had better efficacy and tolerance
than class I drugs (16). This drug was recently reintroduced
in our country, and we observed 67% efficacy in 14 patients
with Chagas' disease and sustained ventricular tachycardia
refractory to drug therapy (12). Like amiodarone, its use
must be extremely cautious in patients with
bradyarrhythmias.
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Finally, it is important to stress that ventricular
function is the most important clinical variable influencing
the prognosis of patients with Chagas' disease and complex
ventricular arrhythmias (17,18). Patients with refractory
ventricular arrhythmias, specially sustained ventricular
tachycardias can be studied with the electrophysiological
(7) techniques. Surgical (26) or catheter ablation (10) of
an arrhythmogenic focus of ventricular tachycardia and
implantation of a cardioverter-defibrillator can be indicated
in patients refractory to all therapeutic options (8).
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